Visit https://www.peervoice.com/QZT860 to view the entire programme with slides. After completing “Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?”, participants will be able to: Discuss the rationale for checkpoint inhibitors in the management of advanced or recurrent endometrial cancer; Evaluate recent data for current and emerging checkpoint inhibitors for the management of advanced or recurrent endometrial cancer; Identify common and serious adverse events associated with checkpoint inhibitors and their management in advanced or recurrent endometrial cancer.